Saturday, March 02, 2024 4:27:22 PM
As such, if I knew I was going blind (as do many fungal patients in S America), I would jump on anything and everything that offered any hope of me keeping my sight.
Brilacidin - has been shown to be a possible treatment (a good chance as I read it), and it has no drastically negative history in trials (if given in proper dosages), so I would jump on a treatment with it in a heartbeat. Give me a moderate dosage and if that doesn't work slowly increase until either it does start working or negative effects come about that would be life threatening (and even then I would take it for another test or two).
I may not be the norm, but I am sure there are many thousands of the million people a year that lose their sight due to fungal infection that would also be willing to try such a drug. At the very least, give 100 to 500 people a test with a hearty dose as determined to be the level to cause a positive reaction. If it proves deadly to all, sorry but thank you greatly for providing data to lower the dosage. Once you get it down to a level that works and is safe (say only 100 people per follow up trial at lower dosage) ;you may have lost less than 1000 people and yet you have saved sight for millions.
To me that is a very fair loss as they were all volunteers and I would be the first to sign up for the initial trial. Hope the powers to be in S. America feel the same way. Don't inch up on the problem as is done in America, go in big to a small test group and then scale back immediately should issues arise. That way you don't take years (as FDA did w/ Kevetrin to find it was safe until effectiveness couldn't go any higher) but maybe only six months or so.
About time medicine started changing ways (as in AI saying if dose should be deadly or not) from the old tried and true methods (unless those on the old system were making too much money under the table to keep trials slow, cumbersome, and IMO totally bullshit in many cases).
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM